Human epidermal growth factor receptor 2 (HER2) amplification or overexpression presents in approximately 15%–20% of breast cancer and correlates with more aggressive clinical phenotype, increased metastatic potential, and shorter survival (1). The gene discussed is ERBB2; the disease is breast cancer.